JP2022533570A5 - - Google Patents

Info

Publication number
JP2022533570A5
JP2022533570A5 JP2021566480A JP2021566480A JP2022533570A5 JP 2022533570 A5 JP2022533570 A5 JP 2022533570A5 JP 2021566480 A JP2021566480 A JP 2021566480A JP 2021566480 A JP2021566480 A JP 2021566480A JP 2022533570 A5 JP2022533570 A5 JP 2022533570A5
Authority
JP
Japan
Prior art keywords
cancer
composition
use according
disorder
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021566480A
Other languages
English (en)
Japanese (ja)
Other versions
JP7527309B2 (ja
JP2022533570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032474 external-priority patent/WO2020231990A1/en
Publication of JP2022533570A publication Critical patent/JP2022533570A/ja
Publication of JP2022533570A5 publication Critical patent/JP2022533570A5/ja
Priority to JP2024117746A priority Critical patent/JP2024156729A/ja
Application granted granted Critical
Publication of JP7527309B2 publication Critical patent/JP7527309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566480A 2019-05-13 2020-05-12 Ｆｇｆｒ阻害剤およびそれらの使用 Active JP7527309B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024117746A JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846991P 2019-05-13 2019-05-13
US62/846,991 2019-05-13
US202062993957P 2020-03-24 2020-03-24
US62/993,957 2020-03-24
US202063011469P 2020-04-17 2020-04-17
US63/011,469 2020-04-17
PCT/US2020/032474 WO2020231990A1 (en) 2019-05-13 2020-05-12 Fgfr inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024117746A Division JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2022533570A JP2022533570A (ja) 2022-07-25
JP2022533570A5 true JP2022533570A5 (https=) 2023-05-19
JP7527309B2 JP7527309B2 (ja) 2024-08-02

Family

ID=73289291

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566480A Active JP7527309B2 (ja) 2019-05-13 2020-05-12 Ｆｇｆｒ阻害剤およびそれらの使用
JP2024117746A Pending JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024117746A Pending JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Country Status (17)

Country Link
US (2) US12522605B2 (https=)
EP (2) EP3968999B1 (https=)
JP (2) JP7527309B2 (https=)
KR (2) KR20260030158A (https=)
CN (2) CN114126620B (https=)
AU (2) AU2020274083B9 (https=)
BR (1) BR112021022457A2 (https=)
CA (1) CA3137458A1 (https=)
CL (1) CL2021002882A1 (https=)
ES (1) ES2974985T3 (https=)
IL (2) IL287940B2 (https=)
MX (1) MX2021013146A (https=)
PE (1) PE20220573A1 (https=)
PH (1) PH12021552862A1 (https=)
SG (1) SG11202111327XA (https=)
TW (1) TWI855070B (https=)
WO (1) WO2020231990A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020231990A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
JP2021017595A (ja) * 2019-07-18 2021-02-15 花王株式会社 アニオン変性セルロース
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
EP4143196A4 (en) 2020-04-29 2024-04-17 Relay Therapeutics, Inc. PI3K-A INHIBITORS AND METHODS OF USE THEREOF
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
CN115160319B (zh) * 2021-04-01 2023-12-26 西安新通药物研究股份有限公司 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
WO2022206939A1 (zh) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 作为fgfr抑制剂的杂环化合物及其应用
CN117677621A (zh) * 2021-08-04 2024-03-08 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
KR20240075952A (ko) * 2021-09-23 2024-05-30 3에이치 파머슈티컬즈 컴퍼니 리미티드 Fgfr 억제제 및 이의 사용 방법
WO2023104035A1 (zh) * 2021-12-06 2023-06-15 英矽智能科技(上海)有限公司 取代的单环或双环杂环化合物，其制法与医药上的用途
JP2025505230A (ja) * 2022-02-08 2025-02-21 上海奕拓醫藥科技有限責任公司 二環式ヘテロアリール化合物およびその使用
EP4499616A4 (en) * 2022-03-31 2025-10-29 Acerand Therapeutics Hong Kong Ltd SPIROBICYLICIOUS COMPOUNDS
WO2023202625A1 (zh) * 2022-04-20 2023-10-26 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法
WO2023220131A2 (en) * 2022-05-10 2023-11-16 Relay Therapeutics, Inc. PI3Kα INHIBITORS AND METHODS OF USE THEREOF
CN117186103A (zh) * 2022-06-01 2023-12-08 安徽诺全药业有限公司 氘代杂环化合物及其制备方法和应用
CN119421872A (zh) * 2022-06-29 2025-02-11 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
TW202412758A (zh) * 2022-06-29 2024-04-01 香港商英矽智能科技知識產權有限公司 Fgfr2與fgfr3抑制劑及其用途
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
AU2023338193A1 (en) * 2022-09-07 2025-03-20 Eli Lilly And Company Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives as fgfr3 inhibitors for the treatment of cancer
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
CN115594682B (zh) * 2022-10-26 2024-03-15 苏州浦合医药科技有限公司 Fgfr2抑制剂
CN120344533A (zh) * 2022-11-22 2025-07-18 海思科医药集团股份有限公司 一种嘧啶衍生物及其在医药上的应用
CN120752227A (zh) * 2023-02-24 2025-10-03 希格生科（深圳）有限公司 α，β-不饱和酰胺类化合物及其应用
CN120712269A (zh) * 2023-03-20 2025-09-26 英矽智能科技知识产权有限公司 Fgfr2和fgfr3的抑制剂及其用途
WO2024208315A1 (zh) * 2023-04-07 2024-10-10 中国医药研究开发中心有限公司 芳香杂环类化合物及其制备方法和医药用途
CN121263414A (zh) * 2023-05-26 2026-01-02 上海艾力斯医药科技股份有限公司 杂芳环类化合物、其药物组合物及其应用
CN119894900A (zh) * 2023-06-05 2025-04-25 康百达（四川）生物医药科技有限公司 一种吡咯并嘧啶衍生物及其在医药上的应用
CN117343068B (zh) * 2023-09-28 2026-04-28 上海相辉医药科技有限公司 一种FGFR2抑制剂Lirafugratinib(RLY-4008)的制备方法
WO2025067484A1 (en) * 2023-09-28 2025-04-03 Acerand Therapeutics (Hong Kong) Limited Crystal forms and salts of spirobicyclic compound
CN121693505A (zh) * 2023-11-17 2026-03-17 上海齐鲁制药研究中心有限公司 含氮杂芳基衍生物、其制备方法及其在医药上的应用
WO2025140636A1 (zh) * 2023-12-29 2025-07-03 广州科恩泰生物医药科技有限公司 一种亚砜亚胺类化合物的酸式盐的晶型及其制备方法和用途
WO2025149021A1 (zh) * 2024-01-10 2025-07-17 海思科医药集团股份有限公司 一种吡啶并吡咯衍生物及其在医药上的应用
WO2025237312A1 (zh) * 2024-05-15 2025-11-20 深圳福沃药业有限公司 一类含苯并异噁唑结构的高选择性fgfr2抑制剂及其制备方法和应用
CN121270563A (zh) * 2024-07-01 2026-01-06 北京鞍石生物科技股份有限公司 稠环化合物及其制备方法和应用
CN120136834B (zh) * 2025-02-13 2026-02-03 浙江工业大学 一种手性吡喃环化合物及其合成方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB119249A (en) 1917-06-09 1918-10-03 Du Pont Process of Producing Alcohols.
US2319070A (en) 1938-03-31 1943-05-11 Eastman Kodak Co Manufacture of unsaturated aliphatic acids and anhydrides
KR100296810B1 (ko) 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
WO1998007726A1 (en) * 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CA2285455A1 (en) 1997-04-09 1998-10-15 Sebastian Mario Marcuccio Process for covalently coupling organic compounds utilizing diboron derivatives
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
RU2358975C2 (ru) 2003-08-26 2009-06-20 Тейдзин Фарма Лимитед Пирролопиримидиноновые производные
US7892354B2 (en) 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
MXPA06015223A (es) * 2004-06-29 2007-11-09 Amgen Inc Furanopirimidinas.
MXPA06015237A (es) 2004-06-29 2007-12-10 Amgen Inc Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
DE102005061170A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102286048A (zh) * 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
MY171055A (en) 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CA3015484C (en) * 2016-02-23 2022-11-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2020231990A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
WO2021052499A1 (zh) 2019-09-20 2021-03-25 上海济煜医药科技有限公司 稠合吡啶酮类化合物及其制备方法和应用
CN114585610A (zh) 2019-10-28 2022-06-03 日本曹达株式会社 2,6-二氧代-3,6-二氢嘧啶化合物以及农业园艺用杀菌剂、杀线虫剂、及医疗用·动物用抗真菌剂
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
US20230219904A1 (en) 2020-04-17 2023-07-13 Syngenta Crop Protection Ag Herbicidal compounds
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法

Similar Documents

Publication Publication Date Title
JP2022533570A5 (https=)
IL287940B1 (en) Fgfr inhibitors and methods of use thereof
JP2023500483A5 (https=)
Park et al. Multimodal management of muscle-invasive bladder cancer
JP2015134825A5 (https=)
Rubin et al. The Genomics of Prostate Cancer: emerging understanding with technologic advances
JP2018140982A5 (https=)
Ponti et al. Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes
JP2022017295A5 (https=)
JP2019523214A5 (https=)
JP2022548057A5 (https=)
WO2015109180A3 (en) Compositions and methods for treatment and detection of cancers
JP2012153722A5 (https=)
JP2017516775A5 (https=)
JP2014527042A5 (https=)
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
CN112888458A (zh) Cldn18的抗体和化疗药物的联合治疗
JP2017526662A5 (https=)
JP2020510050A5 (https=)
JP2023510736A5 (https=)
JP2017507175A5 (https=)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
JP2008154589A5 (https=)
JP2022547331A5 (https=)
JP2017516827A5 (https=)